CureVac N.V. CVAC 深 沪
已收盘 08-15 16:00:00 美东时间
5.48
-0.030
-0.54%
华盛通- 最 高5.535
- 今 开5.48
- 成交量 63.60万股
- 最 低 5.48
- 昨 收 5.51
- 总市值 12.33亿
- 52周最高 5.72
- 市盈率 静 7.01
- 换手率 0.28%
- 52周最低 2.37
- 委 比 71.98%
- 总股本 2.25亿
- 历史最高 151.80
- 量 比 0.57
- 振 幅 1.00%
- 历史最低 2.215
- 每 手 1
- 风险率 0.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CureVac Reports Financial Losses in Mid-2025
CureVac ( ($CVAC) ) has issued an update. CureVac N.V. released its unaudited i...
今天 04:43
CureVac Reports Q2 Revenues Of EUR1.2M, Lower Than EUR14.4M YoY
The decrease year-over-year was primarily driven by lower revenues from GSK following the restructuring of the partnership in July 2024 from a Collaboration into a Licensing Agreement as well as lower sales to CRISPR
08-15 19:58
BioNTech Settles Patent Disputes with CureVac and GSK
BioNTech SE ( ($BNTX) ) has provided an update. On August 7, 2025, BioNTech SE,...
08-11 18:43
氪星晚报｜印度科技巨头塔塔咨询裁员预示人工智能将重塑2830亿美元外包行业；中国工商银行与新开发银行举行工作会谈；CureVac就新冠疫苗专利与BioNTech、辉瑞达成和解
大公司： 京东物流在福州成立供应链科技公司 36氪获悉，爱企查App显示，近日，福州京迅递供应链科技有限公司成立，法定代表人为张明明，注册资本500万元人民币...
08-08 19:17
CureVac与辉瑞/BioNTech专利纠纷达成和解 葛兰素史克(GSK.US)获高额赔偿
CureVac已与辉瑞和BioNTech在美国就mRNA疫苗的长期专利纠纷达成和解协议，这将使CureVac的前合作伙伴葛兰素史克获得最多5亿美元以及未来疫苗销售1%的版税收入。
08-08 16:51
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance.
08-04 22:32
BioNTech posts Q2 beat as revenue more than doubles
BioNTech (NASDAQ:BNTX) ADRs added ~2% in the premarket on Monday after the German vaccine maker exceeded Street forecasts with its Q2 2025 financials, thanks mainly to an over two-fold rise in its rev...
08-04 19:38
BioNTech GAAP EPS of -€1.60, revenue of €260.8M
BioNTech press release (NASDAQ:BNTX): Q2 GAAP EPS of -€1.60. Revenue of €260.8M (+102.6% Y/Y). Revenues for the 2025 financial year €1,700 million - €2,200 million More on BioNTech BioNTech: More Unce...
08-04 18:47
